Phase 1/2 × Terminated × Other hematologic neoplasm × Clear all Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
Phase 1/2 Terminated
8 enrolled 13 charts
NK4AML
Phase 1/2 Terminated
9 enrolled
Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome
Phase 1/2 Terminated
51 enrolled
topMIND
Phase 1/2 Terminated
54 enrolled 23 charts
Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients
Phase 1/2 Terminated
4 enrolled 30 charts
A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Phase 1/2 Terminated
9 enrolled 21 charts
Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients
Phase 1/2 Terminated
15 enrolled
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
Phase 1/2 Terminated
130 enrolled
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Phase 1/2 Terminated
101 enrolled
Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax
Phase 1/2 Terminated
3 enrolled
Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes
Phase 1/2 Terminated
3 enrolled 9 charts
UPCC 25406
Phase 1/2 Terminated
4 enrolled
Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
Phase 1/2 Terminated
24 enrolled 15 charts
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
Phase 1/2 Terminated
93 enrolled 27 charts
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Phase 1/2 Terminated
137 enrolled 31 charts
Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.
Phase 1/2 Terminated
24 enrolled 16 charts
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
Phase 1/2 Terminated
13 enrolled
Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML
Phase 1/2 Terminated
24 enrolled
A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies
Phase 1/2 Terminated
7 enrolled
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase 1/2 Terminated
4 enrolled 8 charts
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS
Phase 1/2 Terminated
67 enrolled
Side_by_Cide
Phase 1/2 Terminated
2 enrolled
Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement
Phase 1/2 Terminated
6 enrolled 13 charts
Phase l/II Study of Ruxolitinib for Acute Leukemia
Phase 1/2 Terminated
27 enrolled 6 charts
CORONADO CLL
Phase 1/2 Terminated
5 enrolled 13 charts
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
Phase 1/2 Terminated
8 enrolled 8 charts
Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy
Phase 1/2 Terminated
6 enrolled
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Phase 1/2 Terminated
17 enrolled 15 charts
Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant
Phase 1/2 Terminated
4 enrolled 7 charts
Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
Phase 1/2 Terminated
9 enrolled 11 charts
Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia
Phase 1/2 Terminated
110 enrolled
A Study Of The Selective PKC-β Inhibitor MS- 553
Phase 1/2 Terminated
60 enrolled 20 charts
R/R
Phase 1/2 Terminated
1 enrolled 4 charts
AML-NET
Phase 1/2 Terminated
1 enrolled
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
Phase 1/2 Terminated
38 enrolled 34 charts
A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System
Phase 1/2 Terminated
109 enrolled 54 charts
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
Phase 1/2 Terminated
46 enrolled 35 charts
SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission
Phase 1/2 Terminated
16 enrolled 14 charts
Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia
Phase 1/2 Terminated
8 enrolled 13 charts
Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)
Phase 1/2 Terminated
40 enrolled
Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML)
Phase 1/2 Terminated
1 enrolled 6 charts
A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)
Phase 1/2 Terminated
21 enrolled 33 charts
A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)
Phase 1/2 Terminated
24 enrolled 19 charts
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
Phase 1/2 Terminated
48 enrolled
Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL
Phase 1/2 Terminated
20 enrolled
A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL
Phase 1/2 Terminated
13 enrolled
A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
Phase 1/2 Terminated
8 enrolled
A Study of ONO-7475 in Patients With Acute Leukemias
Phase 1/2 Terminated
42 enrolled 47 charts
QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab
Phase 1/2 Terminated
43 enrolled 15 charts
IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome
Phase 1/2 Terminated
2 enrolled 14 charts